
Clean Science Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- The company aims to increase plant utilization, targeting 80-85% capacity utilization within 3 years, growing approximately 30% annually.
- For the HALS series, the target is to scale production from current 40-50 tons/month to 200 tons/month by March 2025, signaling strong volume growth.
- New product launches in the HALS portfolio are expected to support revenue growth, with 10 products planned for commercialization in phases over the next 2 quarters.
- Investment of INR 230-335 crores in capex through FY25 and FY26 aims to expand pharma intermediates and other product capacities, supporting future turnover growth.
- Management’s goal is to double turnover with ongoing investments.
- Demand recovery post-destocking phase and resolved market issues (e.g. Guaiacol demand rebound) are expected to drive gradual sales volume increases.
- Domestic market focus is increasing, reducing dependence on China, and supporting revenue diversification.
See what Clean Science management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No specific mention of any current or planned fundraising through debt or equity in the provided transcript.
- Discussion focuses on capex investments totaling around INR335 crores (including INR100 crores capex blocks and INR30 crores pharma intermediates), funded internally or not specified.
- No indications of equity issuance or debt raising to fund these expansions.
- Plans for future capex are based on pilot trials' success, with no mention of external funding needs.
- Emphasis is on project execution, commercialization timelines, and operational updates rather than financing actions.
See what Clean Science management said on order book — free account, 30 seconds.
Capex plans
Yes- Clean Science and Technology has infused INR 335 crores to date in Clean Fino-Chem, with commercialization expected soon (Feb 2024).
- Future capex includes two rounds of INR 100 crores each, dedicated mainly to production blocks, starting April/May and August/September 2024 respectively, assuming pilot trials go well.
- An additional INR 30 crores is planned for pharma intermediates, with the related facility expected to be commercialized by September-October 2024.
- Total committed capex lined up is approximately INR 230 crores for FY25.
- Other projects in the pipeline at pilot scale may lead to further capex decisions in the coming weeks.
- The pharma intermediate plant construction has begun, with plans to commercialize by September-October 2024.
- The company aims to diversify and increase turnover substantially with these investments.
Track Clean Science — get its next earnings analysis in your feed
How does Clean Science rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Clean Science rank in Chemicals & Petrochemicals?
Compare Clean Science against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Clean Science's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…